It was shown that enfortumab vedotin could inhibit breast, bladder, pancreatic, and lung cancer xenografts in mouse models (17) and has been further evaluated in multicenter phase 2 (EV-201; NCT03219333) and global phase 3 (EV-301; NCT03474107) trials, with preliminary results showing 44%-52% objective response rate (ORR) (46, 47) and prolonged survival compared to chemotherapy (48) in metastatic urothelial cancer patients who previously received platinum chemotherapy and anti-PD-1/PD-L1 immunotherapy. The gene discussed is CD274; the disease is lung cancer.